TrialAnnals of the rheumatic diseases2023

Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance.

Christina Charles-Schoeman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.